Contrast Agents and Radiopharmaceuticals | Market Insights | Europe | 2022
Although demand for contrast-enhanced CT for the diagnosis and monitoring of COVID-19 cases has slightly mitigated the impact of the global pandemic on the European contrast agent and radiopharmaceutical market to some extent, pandemic-related declines in the overall volume of diagnostic imaging procedures performed will have a significant negative impact on the European contrast agent and radiopharmaceutical market in the short term. Once the situation improves, the European contrast agent and radiopharmaceutical market will resume slow growth through 2030, driven by rising radiopharmaceutical ASPs and increasing demand for diagnostic imaging procedures for Europe’s aging population, although the market will continue to be hindered by stringent reimbursement regulations and ongoing safety concerns surrounding GBCAs.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals in Europe across an 11-year period.
